BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a consensus rating of “Moderate Buy” by the ten research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.70.

A number of equities analysts recently commented on BCRX shares. Bank of America boosted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, July 1st. Needham & Company LLC reissued a “buy” rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Royal Bank Of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Wedbush boosted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 30th.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company’s stock, valued at $556,145.52. This represents a 51.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its holdings in BioCryst Pharmaceuticals by 8.9% in the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after purchasing an additional 691,988 shares during the last quarter. Alkeon Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 1.7% in the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company’s stock valued at $54,105,000 after purchasing an additional 120,199 shares during the last quarter. Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 1.9% in the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock valued at $45,296,000 after purchasing an additional 93,973 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in BioCryst Pharmaceuticals by 2,103.7% in the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after purchasing an additional 4,084,403 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 1.3%

Shares of BCRX stock opened at $8.08 on Friday. BioCryst Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $11.31. The stock’s 50-day moving average price is $8.49 and its 200-day moving average price is $8.74. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -44.89, a price-to-earnings-growth ratio of 1.86 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The company’s quarterly revenue was up 49.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.06) EPS. As a group, research analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.